Chemomab Therapeutics files Form 6-K
Chemomab Therapeutics filed a Form 6-K on November 3.
Related stories
Lattice Semiconductor shares surge
Lattice Semiconductor shares surged after its profit outlook exceeded market expectations.
M impact | EQUITY | Nov 03, 2026, 03:31 PM UTC
US session market picture: S&P 500 +0.33%, Nasdaq 100 +0.74%; EUR/USD -0.09%, WTI -0.01%, WBD leads volume
US session market picture. US index futures: S and P futures is up 0.33 percent, Nasdaq futures is up 0.74 percent, Dow futures is down 0.53 percent and Russell futures is up 0.69
M impact | EQUITY | Nov 03, 2026, 03:30 PM UTC
Optimus SBR Acquires Greenlight Consulting to Expand AI and Automation Capabilities
The acquisition is intended to expand capabilities for financial institutions, public sector organizations and healthcare.
M impact | EQUITY | Nov 03, 2026, 03:30 PM UTC
Oracle Said To Allocate 65% Of USD 10B Stock Sale To 10 Investors
L impact | EQUITY | Nov 03, 2026, 03:29 PM UTC
Mexico’s Main Stock Index Extends Gains Above 2%
M impact | EQUITY | Nov 03, 2026, 03:28 PM UTC
Sportradar Group Reports Third-Quarter Revenue of EUR362.5M
M impact | EQUITY | Nov 03, 2026, 03:28 PM UTC